Central neurologic complications of HIV infection

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Current Infectious Disease Reports

• Publication date

  1999-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11908-996-0028-2PMID 11095787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Haptoglobin polymorphism, iron metabolism and mortality in HIV infection

  1998cited by this paper
• Localization of HIV-1 co-receptors CCR5 and CXCR4 in the brain of children with AIDS.

  1998cited by this paper
• Prevalence of genotypic resistance to nucleoside analogues in antiretroviral‐naive and antiretroviral‐experienced HIV‐infected patients in Spain

  1998cited by this paper
• Role of the β-Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia

  1998cited by this paper
• Chemokines and receptors in HIV encephalitis

  1998cited by this paper
• A phase I/II trial of nimodipine for HIV-related neurologic complications

  1998cited by this paper
• Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.

  1998cited by this paper
• A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.

  1998cited by this paper
• Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.

  1998cited by this paper
• Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function

  1998cited by this paper
• Chemokines--chemotactic cytokines that mediate inflammation.

  1998cited by this paper
• A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment

  1998cited by this paper
• Chemokine Receptor Utilization by Human Immunodeficiency Virus Type 1 Isolates That Replicate in Microglia

  1998cited by this paper
• Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome

  1997cited by this paper
• CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain.

  1997cited by this paper
• Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.

  1997cited by this paper
• Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brain

  1997cited by this paper
• CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons.

  1997cited by this paper
• Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome

  1996cited by this paper

• Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety.

  2020cites this paper
• Neuroinflammation and Excitotoxicity in Neurobiology of HIV-1 Infection and AIDS: Targets for Neuroprotection

  2007influential citation
• 34 – Molecular Neurology of HIV-1 Infection and AIDS

  2007cites this paper
• Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin

  2005cites this paper
• HIV-1 infection and AIDS: consequences for the central nervous system

  2005cites this paper
• HIV Infection and the Central Nervous System

  2004cites this paper